An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
Background: Gene therapies can treat, prevent, or cure a disease by changing the expression of a person's genes. They are an innovative strategy for treating genetic disorders; however, they are still emerging on the market access and in the healthcare system. Health technology assessment (HTA)...
Saved in:
Main Authors: | Michał Pochopień (Author), Ewelina Paterak (Author), Emilie Clay (Author), Justyna Janik (Author), Samuel Aballea (Author), Małgorzata Biernikiewicz (Author), Mondher Toumi (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The impact of amortization of gene therapies funding on the results and conclusions of CEMs and BIMs
by: Hubert Polek, et al.
Published: (2023) -
Gene Therapy Evidence Generation and Economic Analysis: Pragmatic Considerations to Facilitate Fit-for-Purpose Health Technology Assessment
by: Tingting Qiu, et al.
Published: (2022) -
Cost-Effectiveness Analysis of Innovative Therapies for Patients with Non-Alcoholic Fatty Liver Disease
by: Michal Pochopien, et al.
Published: (2024) -
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
by: Michal Pochopien, et al.
Published: (2019) -
Commentary on "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial" by Gautret et al
by: Mondher Toumi, et al.
Published: (2020)